BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sacituzumab Govitecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sacituzumab Govitecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06329869-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06329869)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 for Advanced Esophageal Squamous Cell Carcinoma\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 acituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06329869
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07163481-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT07163481)
DESCRIPTION:Sacituzumab Govitecan\, phase 1\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Trial to Evaluate Sacituzumab Govitecan in Combination Wi
 th Endocrine Therapy in Patients With HR-positive\, HER2-negative Metastat
 ic Breast Cancer Progressed on CDK4/6 Inhibitors\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07163481
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06065371-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT06065371)
DESCRIPTION:Sacituzumab Govitecan\, phase 1.\nStudy: Sacituzumab Govitecan 
 in Combination With Capecitabine for Advanced Gastrointestinal Cancers Aft
 er Progression on Standard Therapy\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-go
 vitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06065371
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04617522-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT04617522)
DESCRIPTION:Sacituzumab Govitecan\, phase 1.\nStudy: Study of Sacituzumab G
 ovitecan in Participants With Advanced or Metastatic Solid Tumor and Moder
 ate Liver Impairment\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04617522
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05833867-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT05833867)
DESCRIPTION:Sacituzumab Govitecan\, phase 1\, Urothelial Carcinoma.\nStudy:
  Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for
  Muscle Invasive Bladder Cancer\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05833867
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04251416-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04251416)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Study of Sacituzumab
  Govitecan (IMMU-132) in Endometrial Carcinoma\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04251416
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04639986-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04639986)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2
 - Metastatic Breast Cancer (MBC)\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04639986
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682728-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06682728)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelia
 l Carcinoma at High-Risk Recurrence\nEstimated primary completion: 1 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab
 -govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06682728
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05838521-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05838521)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Study of Sacituzumab
  Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Ca
 ncer\nEstimated primary completion: 1 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05838521
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04434040-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04434040)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Atezol
 izumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04434040
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Testin
 g the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab
  and Chemotherapy in Patients With Metastatic Triple Negative Breast Cance
 r\nEstimated primary completion: 30 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03606967
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06528483-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06528483)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle
 -Invasive Bladder Cancer\nEstimated primary completion: 31 December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 28483
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Precision Medicine Tri
 al Based on Molecular Matching Therapy for Patients With Standard Treatmen
 t Exhaustion\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07359404-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07359404)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan Plus Bevacizumab in Metastatic TNBC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07359404
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492914-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07492914)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Neoadjuvant Sacituzuma
 b Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell C
 arcinoma\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07492914
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675579-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05675579)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: A Phas
 e II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy 
 for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer
  (TNBC)\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05675579
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06827613-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06827613)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Invikafusp Alfa (STAR0602)\, a Selective T Cel
 l Receptor (TCR)-Targeting\, Bifunctional Antibody-fusion Molecule\, in Co
 mbination With Sacituzumab Govitecan in Participants With Advanced Solid T
 umors\nEstimated primary completion: January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06827613
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04039230-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT04039230)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study to Evaluate Sacituzumab Govitecan in Combination Wi
 th Talazoparib in Patients With Metastatic Breast Cancer.\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04039230
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04794699-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT04794699)
DESCRIPTION:Sacituzumab Govitecan\, phase 1.\nStudy: Study of IDE397 in Par
 ticipants With Solid Tumors Harboring MTAP Deletion\nEstimated primary com
 pletion: 7 January 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04794699
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Gov
 itecan in Combination With Pembrolizumab for Participants With Metastatic 
 Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD
 -L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary 
 completion: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05609968
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462092-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06462092)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Sacituzumab Govitecan and Intrathecal Chemotherapy for Tr
 eating Leptomeningeal Metastases From Her2-negative Breast Cancer\nEstimat
 ed primary completion: 15 January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06462092
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06462079-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06462079)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sacituzumab Govitecan Combined With Head Radiotherapy for H
 er2-negative Breast Cancer Brain Metastases\nEstimated primary completion:
  15 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sac
 ituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06462079
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03971409-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03971409)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Avelum
 ab With Binimetinib\, Sacituzumab Govitecan\, or Liposomal Doxorubicin in 
 Treating Stage IV or Unresectable\, Recurrent Triple Negative Breast Cance
 r\nEstimated primary completion: 31 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03971409
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06612203-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06612203)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Clinical Study to Evaluate Debio0123 + Sacituzumab Govite
 can Combination in TNBC or HR+/HER2- Advanced Breast Cancer\nEstimated pri
 mary completion: February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06612203
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238921-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06238921)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Saci
 tuzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic T
 riple Negative Breast Cancer With Brain Metastases\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06238921
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535218-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05535218)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk\, Loca
 lized Bladder Cancer\nEstimated primary completion: February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05535218
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382286-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382286)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice and Pembrolizumab in Patients With Previously Untreated\, Loc
 ally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05382286
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04724018-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT04724018)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Urothelial Carcinoma.\nStud
 y: Sacituzumab Govitecan Plus EV in Metastatic UC\nEstimated primary compl
 etion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04724018
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Sacituzumab Tirumotecan Combined With Toripalimab for Rese
 ctable Stage II-IIIB NSCLC\nEstimated primary completion: 28 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7438600
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05186974)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Sacituzumab Govitecan Combinations in First-line Treatment
  of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05186974
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07046455-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Sacituzumab Govitecan: Phase na readout est. (NCT07046455)
DESCRIPTION:Sacituzumab Govitecan\, phase na\, Breast Cancer.\nStudy: Trop-
 2 Targeted PET Probes in Advanced TNBC\nEstimated primary completion: 1 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab
 -govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07046455
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04595565-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT04595565)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sacituzumab Govitecan in Primary HER2-negative Breast Cance
 r\nEstimated primary completion: 30 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04595565
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06409390-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06409390)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequential Therapies Modeled on Evolutionary Dynamics for B
 reast Cancer\nEstimated primary completion: April 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06409390
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04468061-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04468061)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan +/- Pembrolizumab in Metastatic TNBC\nEstimated primary co
 mpletion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04468061
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05101096-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05101096)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of Sacituzumab Govitecan (SG) in Japanese Participa
 nts With Advanced Solid Tumors\nEstimated primary completion: May 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05101
 096
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06248515-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06248515)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Phase II Trial of Sa
 cituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors\nEs
 timated primary completion: May 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06248515
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06665178-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06665178)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Genomic and Transcriptomic Predictors of Sequential SG Sens
 itivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer\nEstimated pr
 imary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06665178
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07040644-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07040644)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Study of Sacituzumab
  Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L
 1 Positive Advanced TNBC\nEstimated primary completion: June 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07040644
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07367178-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07367178)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan With Atropine to Improve Tol
 erability in Advanced TNBC and HR+/HER2- Breast Cancer\nEstimated primary 
 completion: June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07367178
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633654-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05633654)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic
 ian's Choice in Patients With Triple Negative Breast Cancer Who Have Resid
 ual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-
 65 OptimICE-RD/GBG 119/NSABP B-63)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05633654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368543-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07368543)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic B
 reast Cancer\nEstimated primary completion: 1 June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07368543
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07674615-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT07674615)
DESCRIPTION:Sacituzumab Govitecan\, phase 1.\nStudy: IMMU-132 in TROP-2 Ove
 rexpressed Advanced and Relapsed Ovarian Cancer\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07674615
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06878625-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06878625)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: A Mult
 icenter\, Prospective\, Cohort Study of Trop-2 ADC Combination Therapy for
  Advanced Triple-negative Breast Cancer\nEstimated primary completion: 30 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzuma
 b-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06878625
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616987-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06616987)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Preven
 tion of Sacituzumab Govitecan-related Neutropenia in Patients With Metasta
 tic Triple Negative Breast Cancer\nEstimated primary completion: 30 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06616987
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07299409-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07299409)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: First-
 Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Ca
 ncer Patients.\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07299409
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04559230-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04559230)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 in Recurrent Glioblastoma\nEstimated primary completion: August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0455923
 0
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825753-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07825753)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancr
 eatic and Breast Cancer\nEstimated primary completion: 1 September 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0782
 5753
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667167-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06667167)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: First Line Therapy for Extensive SCLC Patients\, Treated with Chemo
 +Keytruda Followed by Keytuda+Trodelvy\nEstimated primary completion: 1 No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06667167
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161532-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06161532)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (S
 MART) Such as High Grade Neuroendocrine Carcinomas\, Adenocarcinoma\, and 
 Squamous Cell Bladder/Urinary Tract Cancer\, Renal Medullary Carcinoma and
  Penile C...\nEstimated primary completion: 1 November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06161532
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235216-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06235216)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab govitEcan 
 in THYroid Cancers\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06235216
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04647916-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04647916)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Testing Sacituzumab Govitecan Therapy in Patients With HER2
 -Negative Breast Cancer and Brain Metastases\nEstimated primary completion
 : 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 acituzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04647916
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05601440)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-in
 hibitor Resistant ER+/HER2- Metastatic Breast Cancer\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063212-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280102
DTEND;VALUE=DATE:20280103
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07063212)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Study of Sacituzumab
  Govitecan in Combination With Cetuximab in People With Head and Neck Squa
 mous Cell Cancer (HNSCC)\nEstimated primary completion: 2 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063
 212
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867251-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT05867251)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Study of AVZO-021 in Patients With Advanced Solid Tumors\
 nEstimated primary completion: 31 January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05867251
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07471776-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280311
DTEND;VALUE=DATE:20280312
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07471776)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study on Using TROP2-PET and 18F-FDG PET to Predict the Eff
 icacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer\nEstimated pri
 mary completion: 11 March 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07471776
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311214-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06311214)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Personalized Antibody-
 Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment 
 of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatm
 ent Trial)\nEstimated primary completion: 31 March 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06311214
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05840211-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05840211)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Study of Sacituzumab Govitecan Versus Treatment of Physicia
 n's Choice in Patients With Hormone Receptor-positive/Human Epidermal Grow
 th Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Hav
 e Received Endocrine Therapy\nEstimated primary completion: April 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05840
 211
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788222-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07788222)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 and Q901 in Advanced TNBC\nEstimated primary completion: 31 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0778822
 2
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926920-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06926920)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: A St
 udy of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in 
 Participants With Advanced Triple-Negative Breast Cancer\nEstimated primar
 y completion: June 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06926920
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263543-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06263543)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA L
 OW MBC\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06263543
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04986579-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04986579)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Scalp Cooling in MBC\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-gov
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04986579
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05382299-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05382299)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: Study 
 of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Pa
 tients With Previously Untreated Locally Advanced Inoperable or Metastatic
  Triple-Negative Breast Cancer\nEstimated primary completion: July 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0538
 2299
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011654-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT07011654)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Tripl
 e-negative Breast Cancer (TNBC)\nEstimated primary completion: 1 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7011654
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05884320-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05884320)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Phase II Trial of Saci
 tuzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers\n
 Estimated primary completion: 31 July 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05884320
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770531-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05770531)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Circulating Tumor DNA 
 to Guide Changes in Standard of Care Chemotherapy\nEstimated primary compl
 etion: 1 August 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05770531
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06243393-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Sacituzumab Govitecan: Phase 2/3 readout est. (NCT06243393)
DESCRIPTION:Sacituzumab Govitecan\, phase 2/3.\nStudy: Sacituzumab Goviteca
 n in Metastatic Colorectal Cancer\nEstimated primary completion: 1 August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-gov
 itecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06243393
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06167317-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sacituzumab Govitecan: Phase 1 readout est. (NCT06167317)
DESCRIPTION:Sacituzumab Govitecan\, phase 1.\nStudy: Study of GS-0201 Alone
  and in Combination in Participants With Advanced Solid Tumors\nEstimated 
 primary completion: September 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06167317
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07947823-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07947823)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: ASTAR:
  Sacituzumab Govitecan For Breast Cancer\nEstimated primary completion: 1 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacit
 uzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07947823
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04230109-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT04230109)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Sacitu
 zumab Govitecan In TNBC\nEstimated primary completion: October 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04230109
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393555-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07393555)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Treatment for Advanced Non-small Cell Lung Cancer With Actionable G
 enomic Alterations After Targeted Treatment and Chemotherapy (An Expanded 
 Lung-MAP Treatment Trial)\nEstimated primary completion: 30 November 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-goviteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 393555
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055465-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06055465)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 30 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6055465
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339059-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07339059)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Study of Sacituzumab G
 ovitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive
 -Stage Small Cell Lung Cancer\nEstimated primary completion: 1 February 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govit
 ecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07339059
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504588-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07504588)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 With Bevacizumab Compared to Usual Chemotherapy (Carboplatin\, Pegylated L
 iposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sens
 itive Ovarian Cancer After PARP Inhibitor Maintenance Therapy\nEstimated p
 rimary completion: 12 April 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07504588
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486441-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06486441)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Endometrial Cancer.\nStudy: S
 tudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Pa
 rticipants With Endometrial Cancer After Platinum-Based Chemotherapy and I
 mmunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)\nEstimated primary comple
 tion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saci
 tuzumab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06486441
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06477419-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290621
DTEND;VALUE=DATE:20290622
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06477419)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: A Study of Sacituzumab
  Govitecan in People With Mesothelioma\nEstimated primary completion: 21 J
 une 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab
 -govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06477419
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633667-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05633667)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Novel Treatment Combinations in Patients With Lung Cancer\
 nEstimated primary completion: September 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05633667
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081244-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06081244)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: NeoAdj
 . Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low
 -risk\, Triple-neg. EBC (ADAPT-TN-III)\nEstimated primary completion: Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzum
 ab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06081244
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151586-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07151586)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Testin
 g Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) C
 ombinations Prescribed in an Alterning Pattern to Patients With Metastatic
  or Locally Advanced Triple-negative Breast Cancer\nEstimated primary comp
 letion: October 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sacituzumab-govitecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07151586
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06801834-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06801834)
DESCRIPTION:Sacituzumab Govitecan\, phase 3.\nStudy: Study of Sacituzumab G
 ovitecan Versus Standard of Care in Participants With Previously Treated E
 xtensive Stage Small Cell Lung Cancer\nEstimated primary completion: Octob
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-
 govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06801834
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06133517-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06133517)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: PeRioperative Immunoth
 erapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cance
 r\nEstimated primary completion: January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06133517
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05332561-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05332561)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: Genomi
 cs Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast 
 Cancer (COGNITION-GUIDE)\nEstimated primary completion: March 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05332561
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06923826-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06923826)
DESCRIPTION:Sacituzumab Govitecan\, phase 2.\nStudy: Sacituzumab Govitecan 
 in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)\nEstimated prim
 ary completion: April 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06923826
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03547973-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT03547973)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Urothelial Carcinoma.\nStudy:
  Study of Sacituzumab Govitecan in Participants With Urothelial Cancer Tha
 t Cannot Be Removed or Has Spread\nEstimated primary completion: April 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govite
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03547973
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study Evaluating the Efficacy and Safety of Multiple Tr
 eatment Combinations in Patients With Metastatic or Locally Advanced Breas
 t Cancer\nEstimated primary completion: 30 September 2030. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963905-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06963905)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Breast Cancer.\nStudy: Saci
  Nivo Rela for TNBC\nEstimated primary completion: December 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06963905
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271992-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20301214
DTEND;VALUE=DATE:20301215
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07271992)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Breast Cancer.\nStudy: TREND-
 02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab
  Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer
 \nEstimated primary completion: 14 December 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07271992
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524544-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06524544)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Urothelial Carcinoma.\nStudy:
  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govite
 can-hziy Versus Standard of Care in the Treatment of Advanced Urothelial C
 ancer\nEstimated primary completion: 31 December 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06524544
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06040970-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20310701
DTEND;VALUE=DATE:20310702
SUMMARY:Sacituzumab Govitecan: Phase 1/2 readout est. (NCT06040970)
DESCRIPTION:Sacituzumab Govitecan\, phase 1/2\, Endometrial Cancer.\nStudy:
  Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive
  Recurrent Ovarian and Endometrial Cancer\nEstimated primary completion: 1
  July 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzum
 ab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06040970
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06431633-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06431633)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Study of Treatment With Sacituzumab and Zimberelimab for Patients W
 ith Lung Cancer Confined to the Chest and Previously Operated on Who Were 
 Not Disease-free.\nEstimated primary completion: 30 November 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06431633
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178730-1992@assetmemo.bio
DTSTAMP:20261121T005011Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT07178730)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Breast Cancer.\nStudy: NeoAdj
 uvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemot
 herapy in Clinical Stage II-III\, Triple-negative Early Breast Cancer\nEst
 imated primary completion: 31 March 2033. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07178730
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
